Navigation Links
K-V Pharmaceutical Secures Financing Commitments Establishing Path Forward For Specialty Pharmaceutical Business
Date:11/17/2010

n the Company assets acting as collateral for the loan agreement, and adversely affect the Company's ability to operate;

(3)  the consent decree between the Registrant and the FDA and the Registrant's suspension of the production and shipment of all of the products that it manufactures (other than the Potassium Chloride products that are the subject of the FDA letter received September 8, 2010) and the related nationwide recall affecting all of the other products that it manufactures, as well as the related material adverse effect on its revenue, assets and liquidity and capital resources, as more fully described in Part I, Item 2 – "Management's Discussion and Analysis of Financial Condition and Results of Operations – Background – Discontinuation of Manufacturing and Distribution; Product Recalls; and the FDA Consent Decree" in the Form 10-Q;

(4)  the plea agreement between the Registrant and the U.S. Department of Justice and the Registrant's obligations therewith, as well as the related material adverse effect, if any, on its revenue, assets and liquidity and capital resources, as more fully described in Note 20 – "Subsequent Events" of the Notes to the Consolidated Financial Statements in the Form 10-Q;

(5)  changes in the current and future business environment, including interest     rates and capital and consumer spending;

(6)  the difficulty of predicting FDA approvals, including timing, and that any period of exclusivity may not be realized;

(7)  the possibility of not obtaining FDA approvals or delay in obtaining FDA approvals, including with respect to Gestiva™, as well as the number of preterm births for which Gestiva™ may be prescribed, its safety profile and side effects profile;

(8)  acceptance of and demand for the Registrant's new pharmaceutical products or current products upon their return to the marketplace;

(9)  new
'/>"/>

SOURCE K-V Pharmaceutical Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014  SCILEX Pharmaceuticals, Inc., a company engaged ... for the treatment of pain, announced that it had formed ... Jeff Gudin , Dr. Charles Argoff , ... Vought . SCILEX Chief Executive Officer ... board would greatly assist in the development and commercialization ...
(Date:8/19/2014)... Colo. , Aug. 19, 2014 ... Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), ... rd Annual Meeting of the American Academy ... Acute Care Surgery in Philadelphia, Pennsylvania ... 2014.  The presentation will report results from a ...
(Date:8/19/2014)... 2014 ,Weight Loss- Market Analysis, ... report provides comprehensive insights about phase III pipeline drugs ... of the report is to establish the understanding for ... across the different countries and regions. While the leading ... also provides details on the drug master filings across ...
Breaking Medicine Technology:SCILEX Pharmaceuticals Announces Scientific Advisory Board 2SCILEX Pharmaceuticals Announces Scientific Advisory Board 3SCILEX Pharmaceuticals Announces Scientific Advisory Board 4Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 3Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 2Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 3Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 4
(Date:8/20/2014)... August 20, 2014 Blaine Labs®, ... innovative RevitaDERM® Psoriasis Treatment to ease ... with psoriasis. This all-in-one product was created to ... Psoriasis Treatment is powered by coal tar and ... with this effective ingredient. , RevitaDERM® Psoriasis ...
(Date:8/20/2014)... BOSTON As people grow older, they often have ... awaken too early in the morning. In individuals with ... tends to be especially pronounced, often leading to nighttime ... researchers at Beth Israel Deaconess Medical Center (BIDMC) and ... why sleep becomes more fragmented with age. Reported online ...
(Date:8/20/2014)... Angeles, CA (PRWEB) August 20, 2014 GBK, ... honor the 2014 Emmy Award Nominees and Presenters at the ... on August 22nd and 23rd in Beverly Hills from 11am ... gifts, refreshments and music by DJ Morgan Hildebrand. , As ... fundraising and will feature several charities at the lounge. GO ...
(Date:8/20/2014)... Kowa Optimed returns after a short ... the new SL-17 portable slit lamp. , The SL-17 ... source controlled by an illuminated thumb wheel for easy ... commercially available AAA rechargeable and dry cell batteries, which ... batteries designed specifically for the device. The new Sl-17 ...
(Date:8/20/2014)... Over 31 million Americans suffer from low back ... pain is the single leading cause of disability worldwide, and ... Americans spend at least $50 billion each year trying to ... pain are not due to organic conditions such as arthritis; ... a busy accountant, had little time for physical activity or ...
Breaking Medicine News(10 mins):Health News:RevitaDERM® Psoriasis Treatment Now Available At Over 7,600 CVS/pharmacies 2Health News:Research helps explain why elderly have trouble sleeping 2Health News:Research helps explain why elderly have trouble sleeping 3Health News:GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills 2Health News:GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills 3Health News:GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills 4Health News:Kowa Optimed (Booth MS13043) to Debut New Portable Slit Lamp at 2014 Vision Expo West in Las Vegas, Nevada 2Health News:Physical Therapists Learn to Relieve Low Back Pain 2
... ... Local Academy Offers Training & Education , ... (PRWEB) February 5, 2010 -- During these difficult economic times, we are ... the job to apply for just isn’t there. There is one piece of advice that ...
... , NEW YORK ... (HSS), a world leader in orthopedics and rheumatology, today announced ... launched campaign, "Moving is the Best Medicine," to raise awareness ... , "Like the Arthritis Foundation, we are focusing our extensive ...
... TSX:HAE , MONTREAL , Feb. 5 /PRNewswire-FirstCall/ - ... extension until March 22, 2010 of the delay within ... to make a proposal to its creditors it filed on ... Canada ). This extension is intended to allow Haemacure to complete ...
... , , BEIJING, CHINA , Feb. 5 /PRNewswire-FirstCall/ ... a certain previously released news announcements namely January 7 2009, ... 12,2010 , and January 22, 2010 . , These are significant ... are now starting to crystallize and are beginning to transform HTDS from ...
... in training and bioethicists at Johns Hopkins have created ... quickly assess a patient,s decision-making capacity in an emergency. ... to use it, will be published in the February ... and Communicate, Understand, Reason, Value, Emergency and Surrogate. Doctors ...
... to misuse prescribed drugs, suffer flareups , FRIDAY, ... use herbal remedies experience increased symptoms and poorer quality ... 326 asthma patients for 33 months. Of those patients, ... prescribed inhaled corticosteroids (ICS) less often than other patients. ...
Cached Medicine News:Health News:Addiction Industry Thrives Amidst Economic Climate, Seeks Certified Candidates 2Health News:HSS Supports Arthritis Foundation Focus on Raising National Awareness of Osteoarthritis 2Health News:HSS Supports Arthritis Foundation Focus on Raising National Awareness of Osteoarthritis 3Health News:HSS Supports Arthritis Foundation Focus on Raising National Awareness of Osteoarthritis 4Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 2Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 3Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 4Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 5Health News:Bioethics memory aid can help assess patient decision-making capacity in medical emergencies 2Health News:Bioethics memory aid can help assess patient decision-making capacity in medical emergencies 3Health News:Herbals Not the Answer for Asthma, Study Shows 2
... iMRI is a neurosurgical OR that ... diagnostic tools, including iMRI, necessary to ... iMRI, neurosurgical treatments are performed in ... designed for MR compatibility and safety, ...
... Neuropack M1 is an advanced ... system. It is a sophisticated 2 ... MEB-2200. 2 electrical stimulations, 2 sound ... goggles stimulation. You can customize each ...
Every so often a new product comes along that isn't a small step but a giant leap ahead of everything that has preceeded it. Such is the impact of the Fidelity IAB....
... Dimension cardiovascular ultrasound system is the world's ... fully integrated real-time 4D and multi-dimensional imaging ... member of the Vivid 7 family, provides ... diagnosing heart conditions such as heart failure ...
Medicine Products: